The GLP-1 agonist class of diabetes drugs is known to be effective in helping patients reduce weight and HbA1c. Oral semaglutide, currently in phase 3 trials, would be the first non-injectable drug in this class. Compared with placebo, the trial found people with type 2 diabetes had significant reductions in HbA1c and weight loss while taking oral semaglutide. Read more